Back to School: How biopharma can reboot drug development. Access exclusive analysis here

Hepatitis C: INNX started an open-label extension of a Phase II study in 34 of the 35 patients enrolled in the original study. The protocol calls for 6 E1 vacci

Innogenetics N.V. (EASD:INNX), Ghent, Belgium
Product: Hepatitis C (HCV) E1 vaccine
Business:

Read the full 123 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE